Biofilm-producing and carbapenems-resistant Escherichia coli nosocomial uropathogens: a cross-sectional study.

Publisher: Springer Nature Country of Publication: Switzerland NLM ID: 9816585 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-1905 (Electronic) Linking ISSN: 11396709 NLM ISO Abbreviation: Int Microbiol Subsets: MEDLINE

Publication: 2018- : Switzerland AG : Springer Nature
Original Publication: Barcelona, Spain : Springer, c1998-

Biofilms*/drug effects ; Biofilms*/growth & development ; Cross Infection*/microbiology ; Escherichia coli Infections*/microbiology ; Anti-Bacterial Agents*/pharmacology ; Uropathogenic Escherichia coli*/drug effects ; Uropathogenic Escherichia coli*/genetics ; Uropathogenic Escherichia coli*/physiology ; Uropathogenic Escherichia coli*/isolation & purification ; Urinary Tract Infections*/microbiology; Humans ; Cross-Sectional Studies ; Female ; Male ; Middle Aged ; Carbapenems/pharmacology ; Adult ; Aged ; Risk Factors ; Microbial Sensitivity Tests ; beta-Lactamases/genetics ; beta-Lactamases/metabolism ; Tertiary Care Centers

Objectives: This cross-sectional study aims to determine the incidence and potential risk factors associated with biofilm-producing uropathogenic Escherichia coli (UPEC) nosocomial strains from a tertiary care hospital and to examine the prospective correlation between biofilm generation and antibiotic resistance phenotypes and genotypes.
Methods: A total of 130 UPEC nosocomial isolates were identified, their biofilm formation was quantified using a modified microtiter plate assay, and their antibiotic susceptibilities were assessed utilizing the disc diffusion method. Isolates were then subjected to PCR assays targeting bla KPC , bla VIM , bla IMP , and blaOXA48 genes.
Results: Over half of the isolates (n = 76, 58.5%) were biofilm producers. Among 17 carbapenem-resistant isolates, 6 (42.9%) isolates harbored the bla OXA48 gene, and only 1 (9.1%) isolate was positive for the bla VIM gene. Prior antibiotic therapy (aOR 15.782, p 0.000) and diabetes mellitus DM (aOR 11.222, p 0.016) were the significant risk factors associated with biofilm production, as determined by logistic regression analysis of the data. In addition, gentamicin resistance was the only statistically significant antibiotic resistance pattern associated with biofilm production (aOR 9.113, p 0.02).
Conclusions: The findings of this study emphasize the significance of implementing proper infection control measures to avoid the horizontal spread of biofilm formation and associated antimicrobial resistance patterns among UPEC nosocomial strains.
Competing Interests: Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the Faculty of Medicine Zagazig University (protocol code 63643/29–9-2020). Consent to participate: Informed consent was obtained from all subjects involved in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)

Braz J Microbiol. 2023 Mar;54(1):259-277. (PMID: 36577889)
Int J Microbiol. 2021 Feb 22;2021:8869275. (PMID: 33688348)
Eur Urol. 2020 Nov;78(5):645-646. (PMID: 32616407)
J Diabetes Res. 2016;2016:6573215. (PMID: 26844231)
Indian J Pathol Microbiol. 2016 Apr-Jun;59(2):177-9. (PMID: 27166035)
Braz J Infect Dis. 2020 May - Jun;24(3):231-238. (PMID: 32325019)
J Infect Dev Ctries. 2021 May 31;15(5):696-703. (PMID: 34106894)
Braz J Infect Dis. 2011 Jul-Aug;15(4):305-11. (PMID: 21860999)
Diagn Microbiol Infect Dis. 2011 May;70(1):119-23. (PMID: 21398074)
Med Sci (Basel). 2017 Dec 21;6(1):. (PMID: 29267233)
Antibiotics (Basel). 2021 Apr 26;10(5):. (PMID: 33925772)
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33. (PMID: 20805405)
Am J Infect Control. 2008 Jun;36(5):309-32. (PMID: 18538699)
Int J Clin Pract. 2022 Sep 16;2022:9520362. (PMID: 36187911)
J Hosp Infect. 2015 Sep;91(1):35-44. (PMID: 26187533)
Lett Appl Microbiol. 2019 Apr;68(4):277-293. (PMID: 30811615)
PLoS Med. 2007 Oct 16;4(10):e297. (PMID: 17941715)
APMIS. 2007 Aug;115(8):891-9. (PMID: 17696944)
Biomed Res Int. 2019 Sep 19;2019:1474578. (PMID: 31641666)
Ann Clin Microbiol Antimicrob. 2016 Apr 06;15:20. (PMID: 27048322)
Antibiotics (Basel). 2021 Nov 05;10(11):. (PMID: 34827287)
Front Microbiol. 2019 Apr 29;10:846. (PMID: 31110496)
Nat Rev Microbiol. 2015 May;13(5):269-84. (PMID: 25853778)
Infect Drug Resist. 2020 Jul 14;13:2311-2321. (PMID: 32765007)
J Lab Physicians. 2019 Jan-Mar;11(1):17-22. (PMID: 30983797)
Saudi J Med Med Sci. 2022 Jan-Apr;10(1):1-11. (PMID: 35283714)
Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
BMC Infect Dis. 2020 Jun 29;20(1):453. (PMID: 32600258)
Diabetes Metab Syndr Obes. 2015 Feb 26;8:129-36. (PMID: 25759592)
Int J Mol Sci. 2021 Jul 31;22(15):. (PMID: 34361044)
PLoS One. 2022 Jan 25;17(1):e0262984. (PMID: 35077517)
Antimicrob Resist Infect Control. 2019 May 16;8:76. (PMID: 31131107)
Microorganisms. 2022 Jul 14;10(7):. (PMID: 35889146)
Microorganisms. 2020 Oct 14;8(10):. (PMID: 33066595)
Pol J Microbiol. 2019 Dec;68(4):403-415. (PMID: 31880885)
Open Microbiol J. 2017 Apr 28;11:53-62. (PMID: 28553416)
Emerg Infect Dis. 2006 Aug;12(8):1209-13. (PMID: 16965699)

Keywords: E. coli; Biofilm; Carbapenem resistance; UPEC; Uropathogens

0 (Anti-Bacterial Agents)
0 (Carbapenems)
EC 3.5.2.6 (beta-Lactamases)

Date Created: 20240315 Date Completed: 20241202 Latest Revision: 20241205

20241209

PMC11611923

10.1007/s10123-024-00495-w

38489099